![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Changes in Inflammatory Biomarkers and Baseline Variables After Switching to
Dolutegravir/Lamivudine (DTG/3TC) in 2 Randomized Clinical Trials of Virologically
Suppressed Adults: 48-Week Pooled Analysis
|
|
|
AIDS 2022 July 29-Aug 1 Montreal
Josep M. Llibre,1 Stefan Scholten,2 Olayemi Osiyemi,3 Richard Grove,4 James Oyee,4 Ruolan Wang,5 Brian Wynne,5 Cynthia Donovan,5 Bryn Jones,6 Chinyere Okoli,6
Michelle Kisare,7 Mounir Ait-Khaled6
1Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 2Praxis Hohenstaufenring, Cologne, Germany; 3Triple O Research Institute PA, West Palm Beach, FL, USA; 4GSK, Brentford, UK; 5ViiV Healthcare,
Durham, NC, USA; 6ViiV Healthcare, Brentford, UK; 7GSK, Nairobi, Kenya
![0803221copy](../images/080322/080322-8/0803221copy.gif)
![0803222copy](../images/080322/080322-8/0803222copy.gif)
![0803223copy](../images/080322/080322-8/0803223copy.gif)
![0803224copy](../images/080322/080322-8/0803224copy.gif)
![0803225opy](../images/080322/080322-8/0803225opy.gif)
![0803226copy](../images/080322/080322-8/0803226copy.gif)
![0803227copy](../images/080322/080322-8/0803227copy.gif)
![0803228copy](../images/080322/080322-8/0803228copy.gif)
![0803229copy](../images/080322/080322-8/0803229copy.gif)
![08032210copy](../images/080322/080322-8/08032210copy.gif)
![08032211copy](../images/080322/080322-8/08032211copy.gif)
![08032212copy](../images/080322/080322-8/08032212copy.gif)
![08032213copy](../images/080322/080322-8/08032213copy.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|